Ever Supreme Bio Technology Co., Ltd (TPEX: 6712)

Market Cap	14.12B
Revenue (ttm)	844.86M
Net Income (ttm)	254.33M
Shares Out	80.67M
EPS (ttm)	3.15
PE Ratio	55.59
Forward PE	n/a
Dividend	5.45 (3.12%)
Ex-Dividend Date	May 29, 2024

Volume	135,571
Open	174.50
Previous Close	174.50
Day's Range	173.50 - 175.00
52-Week Range	166.00 - 215.00
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2024

About Ever Supreme Bio Technology

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6712

Financial Performance

In 2023, Ever Supreme Bio Technology's revenue was 758.39 million, an increase of 20.86% compared to the previous year's 627.51 million. Earnings were 539.40 million, an increase of 168.74%.